Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Emma Walmsley

- PMLiVE

Sanofi, GSK’s COVID-19 vaccine generates strong immune responses across all age groups

Sanofi/GSK delayed their COVID-19 vaccine programme in December 2020 after the vaccine candidate induced low immune responses in older adults

- PMLiVE

Positive results for GSK/CureVac’s COVID-19 vaccine

Vaccine candidate generated strong immune responses in preclinical testing

- PMLiVE

EMA launches rolling review of GSK/Vir Biotech’s mAb for early COVID-19

Rolling review supported by interim analysis of data from phase 3 COMET-ICE trial

- PMLiVE

GSK’s revenue drops by 18% in Q1 as performance pressures mount

Chief executive Emma Walmsley said results ‘reflect the anticipated impacts of COVID-19’

Lucid Group is building its data analytics capability

Lucid Group is building a new data analytics capability into its teams with the appointment of Darren Selmes as its new analyst. This appointment signals the start of a stronger...

Lucid Group Communications Limited

- PMLiVE

GSK wins approval for anti-PD-1 antibody Jemperli in endometrial cancer

AnaptysBio earns a $20m milestone payment on approval after originally developing the drug

- PMLiVE

Lucid Group promotes Clare Reynolds to Director of Business Development and Commercial Integration

As Lucid continues to evolve, its people have remained at the heart of its success. Clare Reynolds has played a key part in Lucid’s journey for nearly 12 years, during...

Lucid Group Communications Limited

- PMLiVE

GSK discontinues two feladilimab trials in head and neck cancer

Decision made after recommendation from Independent Data Monitoring Committee

Lucid Group Bolster its Senior Leadership Team

Lucid Group are delighted to welcome Jo Troman to the role of Managing Partner for team Origins. Jo has a wealth of industry experience from both client and agency sides....

Lucid Group Communications Limited

- PMLiVE

GSK to assist in manufacturing up to 60 million doses of Novavax’s COVID-19 vaccine in the UK

Vaccine candidate is expected to be submitted to UK regulatory authorities in Q2

- PMLiVE

Lilly, Vir and GSK’s antibodies reduce viral load by 70% in low-risk COVID-19 patients

The two neutralising antibodies bind to different epitopes of the SARS-CoV-2 spike protein

- PMLiVE

EU, UK working towards a ‘win-win’ situation to expand COVID-19 vaccine supplies

EU leaders are set to meet today to discuss proposed vaccine export plans

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links